selective TGFβR1 kinase inhibitor
completed oral CV studies in higher species
from data mining of internal matter and opt.
ACS Med. Chem. Lett. 11, 172-178
Bristol-Myers Squibb, Princeton, NJ
BMS-986260
1 min read
BMS-986260 (Bristol Myers Squibb (BMS) oral in vivo selective TGF-beta-R1 kinase inhibitor)
Search By Structure
- LNP023
- LMB763 (nidufexor)
- ABBV-744
- AG-881
- FT-2102 (olutasidenib)
- GS-9876 (lanraplenib)
- “compound 25”
- “compound 25”-2
- WF-47-JS03
- BMS-986260
- GNF2133
Molecules of the Month
2023
2022
2021
2020